390 related articles for article (PubMed ID: 32684165)
1. Late-onset ovarian hyperstimulation syndrome developing during ovarian stimulation in an ectopic pregnancy: a case report.
Huang H; Takai Y; Samejima K; Narita T; Ichinose S; Itaya Y; Ono Y; Matsunaga S; Saitoh M; Baba K; Hayashi N; Seki H
J Med Case Rep; 2020 Jul; 14(1):110. PubMed ID: 32684165
[TBL] [Abstract][Full Text] [Related]
2. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
3. Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial.
Mai Q; Hu X; Yang G; Luo Y; Huang K; Yuan Y; Zhou C
Am J Obstet Gynecol; 2017 Jan; 216(1):42.e1-42.e10. PubMed ID: 27555316
[TBL] [Abstract][Full Text] [Related]
4. Severe ovarian hyperstimulation syndrome after combined GnRH-agonist and low-dose human chorionic gonadotropin trigger in a patient with a single kidney.
Pereira N; Lekovich JP; Kligman I; Rosenwaks Z
Gynecol Endocrinol; 2017 Aug; 33(8):593-597. PubMed ID: 28440686
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome.
Jellad S; Haj Hassine A; Basly M; Mrabet A; Chibani M; Rachdi R
J Gynecol Obstet Hum Reprod; 2017 Jan; 46(1):87-91. PubMed ID: 28403961
[TBL] [Abstract][Full Text] [Related]
6. Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction.
Araujo E; Bernardini L; Frederick JL; Asch RH; Balmaceda JP
J Assist Reprod Genet; 1994 Feb; 11(2):74-8. PubMed ID: 7819706
[TBL] [Abstract][Full Text] [Related]
7. A rare presentation of endogenous human chorionic gonadotrophin associated severe ovarian hyperstimulation in the second trimester: a case report.
Fessehaye A; Gudu W
J Med Case Rep; 2021 Jul; 15(1):338. PubMed ID: 34229734
[TBL] [Abstract][Full Text] [Related]
8. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous early pregnancy with very low levels of progesterone during controlled ovarian stimulation-A case report.
Majumdar A; Joshi R
JBRA Assist Reprod; 2022 Nov; 26(4):675-676. PubMed ID: 34995048
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.
Griesinger G; Verweij PJ; Gates D; Devroey P; Gordon K; Stegmann BJ; Tarlatzis BC
PLoS One; 2016; 11(3):e0149615. PubMed ID: 26950065
[TBL] [Abstract][Full Text] [Related]
11. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
[TBL] [Abstract][Full Text] [Related]
12. [Research on the protocol of limited ovarian stimulation to prevent ovarian hyperstimulation syndrome].
Zhu YM; Gao HJ; He RH; Huang HF
Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):740-4. PubMed ID: 17327030
[TBL] [Abstract][Full Text] [Related]
13. Ovarian hyperstimulation syndrome in a frozen-thawed embryo transfer pregnancy: a rare case report.
Yang L; Wang R; Wang F; Wang F; Zou L
BMC Pregnancy Childbirth; 2020 May; 20(1):313. PubMed ID: 32434545
[TBL] [Abstract][Full Text] [Related]
14. Successful pregnancies in patients with estrogenic anovulation after low-dose human chorionic gonadotropin therapy alone following hMG for controlled ovarian hyperstimulation.
Lee KL; Couchman GM; Walmer DK
J Assist Reprod Genet; 2005 Jan; 22(1):37-40. PubMed ID: 15807221
[TBL] [Abstract][Full Text] [Related]
15. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
[TBL] [Abstract][Full Text] [Related]
16. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
[TBL] [Abstract][Full Text] [Related]
17. [GnRH agonist triggering in IVF and luteal phase support in women at risk of ovarian hyperstimulation syndrome].
Guivarc'h-Levêque A; Jaffré F; Homer L; Moy L; Priou G; Colleu D; Denis I; Arvis P
Gynecol Obstet Fertil; 2013 Sep; 41(9):511-4. PubMed ID: 23972925
[TBL] [Abstract][Full Text] [Related]
18. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
[TBL] [Abstract][Full Text] [Related]
19. Current Medical Strategies in the Prevention of Ovarian Hyperstimulation Syndrome.
Kasum M; Orešković S; Franulić D; Čehić E; Lila A; Vujić G; Grgić F
Acta Clin Croat; 2017 Mar; 56(1):133-142. PubMed ID: 29120551
[TBL] [Abstract][Full Text] [Related]
20. Ovarian hyperstimulation syndrome: a clinical report on 4894 consecutive ART treatment cycles.
Sousa M; Cunha M; Teixeira da Silva J; Oliveira C; Silva J; Viana P; Barros A
Reprod Biol Endocrinol; 2015 Jun; 13():66. PubMed ID: 26100393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
